- Home
- INMB
as 12-20-2024 4:00pm EST
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products includeINKmune, INBO3, XPro1595, LIVNate, and others.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | BOCA RATON |
| Market Cap: | 112.0M | IPO Year: | 2019 |
| Target Price: | $21.00 | AVG Volume (30 days): | 215.6K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.19 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.32 - $14.74 | Next Earning Date: | 10-31-2024 |
| Revenue: | $42,000 | Revenue Growth: | -81.25% |
| Revenue Growth (this year): | -93.16% | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of INmune Bio Inc. Common stock (INMB)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Moss David J | INMB | Chief Financial Officer | Sep 30 '24 | Buy | $5.29 | 10,000 | $52,868.00 | 1,285,869 |
Latest INmune Bio Inc. Common stock News
INMB Breaking Stock News: Dive into INMB Ticker-Specific Updates for Smart Investing
GlobeNewswire
12 days ago
INmune Bio Inc. Completes Repayment of Silicon Valley Bank Debt
Exec Edge
18 days ago
OmniScience and INmune Bio Partner for Alzheimer’s Trial
MT Newswires
18 days ago
INmune Bio Partners With OmniScience to Accelerate Alzheimer's Trial
Business Wire
18 days ago
OmniScience Inc. and INmune Bio Inc. Partner to Accelerate a Phase 2 Alzheimer’s Trial with Vivo, a Novel genAI Clinical Trial Control Tower
GlobeNewswire
a month ago
INmune Bio Inc. Announces Final Enrollment of 208 Patients in Phase 2 Trial in Early Alzheimer's Disease
Simply Wall St.
2 months ago
INmune Bio Third Quarter 2024 Earnings: US$0.60 loss per share (vs US$0.48 loss in 3Q 2023)
GuruFocus.com
2 months ago
INmune Bio Inc (INMB) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges and ...
GlobeNewswire
2 months ago
INmune Bio Inc. Announces Third Quarter 2024 Results and Provides Business Update
Compare INMB vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "INMB INmune Bio Inc. Common stock - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.